Kinase regulation of human MHC class i molecule expression on cancer cells

Cancer Immunology Research

Volumn 4, Issue 11, 2016, Pages 936-947

  Brea, Elliott J ^a,b   Oh, Claire Y ^a,b   Manchado, Eusebio ^a   Budhu, Sadna ^a   Gejman, Ron S ^a,b   Mo, George ^a   Mondello, Patrizia ^a   Han, James E ^a,b   Jarvis, Casey A ^a   Ulmert, David ^a   Xiang, Qing ^a   Chang, Aaron Y ^a,b   Garippa, Ralph J ^a   Merghoub, Taha ^a   Wolchok, Jedd D ^a,b   Rosen, Neal ^a,b   Lowe, Scott W ^a,b,c   Scheinberg, David A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHOTRANSFERASE; PROTEIN RET; SHORT HAIRPIN RNA; TRAMETINIB; CD274 PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASM; MESOTHELIOMA CELL LINE; MOUSE; MULTIPLE CANCER; NONHUMAN; NORMAL HUMAN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CD8+ T LYMPHOCYTE; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MAPK SIGNALING; METABOLISM; NEOPLASM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASMS; PHOSPHOTRANSFERASES; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85016108628     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0177     Document Type: Article

References (50)

1. Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res 2000;9:795-812.
2. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
3. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013;5:176ra33.
4. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99:16168-73.
5. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013;5:174ra27.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
7. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
8. Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 2015;14:603-22.
9. Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res 2016;1683-90.
10. CampoliM, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008;27:5869-85.
11. Leone P, Shin E-C, Perosa F, Vacca A,Dammacco F, Racanelli V.MHCclass I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 2013;105:1172-87.
12. Kageshita T,Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma. AmJ Pathol 1999;154:745-54.
13. Paul P, Van Den Hoorn T, Jongsma MLM, Bakker MJ, Hengeveld R, Janssen L, et al. A genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell 2011;145: 268-83.
14. Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-Arm, phase 2 trial. Lancet Oncol 2013;14:1104-11.
15. Veomett N,Dao T, Liu H, Xiang J, PankovD, Dubrovsky L, et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res 2014;20:4036-46.
16. Zuber J, McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ, et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol 2011;29:79-83.
17. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013;5:1704-13.
18. Politi K, Zakowski MF, Fan P-D, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to downregulation of the receptors. Genes Dev 2006;20:1496-510.
19. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcomeamajor drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10.
20. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
21. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition ofmelanomacells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
22. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
23. Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 2011;6:864-74.
24. Chang A, Dao T, Scott A, Dubrovsky L, Liu C, Scheinberg D. A therapeutic TCR mimic monoclonal antibody for intracellular PRAME protein in leukemias. Am Soc Hematol 2015;126:2527.
25. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1467-79.
26. CrossDAE, Ashton SE, Ghiorghiu S, Eberlein C, NebhanCA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61.
27. Girdlestone J, Isamat M, Gewert D, Milstein C. Transcriptional regulation of HLA-A and-B: differential binding of members of the Rel and IRF families of transcription factors. Proc Natl Acad Sci U S A 1993; 90:11568-72.
28. Wolchok JD, Vilcek J. Induction of HLA class I mRNA by cytokines in human fibroblasts: comparison of TNF, IL-1 and IFN-b;. Cytokine 1992;4:520-7.
29. Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2013;2:e26491.
30. Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 2010;207:223-35.
31. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
32. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015;348:124-8.
33. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
34. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 2015;350:207-11.
35. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatoryantibodies targeting PD1, PD-L1 and CTLA-4. Clin Cancer Res 2015;21:1639-51.
36. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015;7:279ra41.
37. Kortum RL, Rouquette-Jazdanian AK, Samelson LE. Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells. Trends Immunol 2013;34:259-68.
38. Ebert PJR, Cheung J, Yang Y, Kim JM, Belvin M, Mellman I, et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 2016;44:609-21.
39. Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux A-L, et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res 2014;2:351-60.
40. Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, et al. Paradoxical activation of T cells via augmented ERK signalingmediated by a RAF inhibitor. Cancer Immunol Res 2014;2:70-9.
41. Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS. The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. Oncoimmunology 2014;3:e946367.
42. Gobin SJP, Biesta P, Van den Elsen PJ. Regulation of human b2-microglobulin transactivation in hematopoietic cells. Blood 2003;101:3058-64.
43. Wolchok D, Goodman A. induction cells of NF-xB may be necessary but is not sufficient for of H-2 antigens by TNF in J558L murine myeloma. Cytokines 1994;55:7-12.
44. Gobin SJP, Peijnenburg A, Van Eggermond M, Van Zutphen M, Van Den Berg R, Van Den Elsen PJ. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and B2-microglobulin genes. Immunity 1998;9:531-41.
45. Zaidi MR, Merlino G. The two faces of interferon-g in cancer. Clin Cancer Res 2011;17:6118-24.
46. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011;17:4400-13.
47. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua L-F, So J, et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 2013;191:6261-72.
48. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000;55:140-8.
49. Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitisinsights into pathogenesis. Nat Rev Rheumatol 2016;12:81-91.
50. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-28.